Lingrui Pharma(SH:600285) Xin Lang Cai Jing·2025-12-31 14:50Core Viewpoint - The resignation of Wu Huibin, the Deputy General Manager of Henan Lingrui Pharmaceutical, is due to internal adjustments, and he will continue to serve as the Chairman and General Manager of a subsidiary, Yingu Pharmaceutical [1][3][5]. Company Information - Henan Lingrui Pharmaceutical is a national high-tech enterprise and A-share listed company primarily engaged in the production and operation of pharmaceuticals and medical devices [3][8]. - The company offers over a hundred products in various forms, including rubber plasters, tablets, capsules, and ointments, covering fields such as orthopedics, neurology, respiratory medicine, anesthesia, and dermatology [3][8]. - The "Two Tigers" series of classic plasters has annual sales exceeding 1 billion pieces, and several products are exclusive to the company [3][8]. Financial Performance - For the first three quarters of 2025, the company's main revenue reached 3.041 billion yuan, representing a year-on-year increase of 10.23% [4][8]. - The net profit attributable to the parent company was 651 million yuan, up 13.43% year-on-year [4][8]. - The net profit after deducting non-recurring gains and losses was 605 million yuan, reflecting an 11.77% increase compared to the previous year [4][8].